Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethacrynic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 14/20 | 1.00 |
| ▸ | GSTA1 | P08263 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | PLIN1 | O60240 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | MAP2K6 | P52564 | 1/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 1/20 | 1.00 |
| ▸ | GSTO1 | P78417 | 1/20 | 1.00 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethacrynic Acid SCHEMBL9108011 | 1.00 | GSTP1 (1.00) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL26353 | 1.00 | GSTP1 (1.00) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL2482896 | 0.99 | GSTP1 (0.97) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL905726 | 0.99 | GSTP1 (0.97) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL3713733 | 0.99 | GSTP1 (0.97) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL18263238 | 0.93 | GSTP1 (0.86) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL8907134 | 0.92 | GSTP1 (0.84) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL10001217 | 0.89 | GSTP1 (0.81) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL10543330 | 0.89 | GSTP1 (0.81) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL9717560 | 0.89 | GSTP1 (0.80) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| EP-4648761-A1 | METHODS OF TREATMENT USING LOOP DIURETICS | scPharmaceuticals Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4590276-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF LOOP DIURETICS AND METHODS OF ADMINISTERING THE SAME | scPharmaceuticals Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-3737233-B1 | GROWTH FACTOR OTIC FORMULATIONS | DOMPE FARM SPA (IT) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066860-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2025-02-27 | — | — | US | disclosed |
| CN-119390664-A | Crystal form of compound containing alpha, beta unsaturated ketone and preparation method thereof | 山东大学 | 2025-02-07 | — | — | CN | disclosed |
| US-12195803-B2 | Methods and materials for assessing and treating cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024151502-A1 | METHODS OF TREATMENT USING LOOP DIURETICS | SCPHARMACEUTICALS INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| WO-2024064027-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF LOOP DIURETICS AND METHODS OF ADMINISTERING THE SAME | SCPHARMACEUTICALS INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-4337642-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | Universite Euro-Mediterraneenne de Fes (MA) | 2024-03-20 | — | — | EP | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20230190642-A1 | GROWTH FACTOR OTIC FORMULATIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2023-06-22 | — | — | US | disclosed |
| US-20230122991-A1 | GROWTH FACTOR FORMULATION FOR CONDITION ASSOCIATED WITH OTIC EVENT | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2023-04-20 | — | — | US | disclosed |
| EP-4093387-A1 | GROWTH FACTOR FORMULATION FOR CONDITION ASSOCIATED WITH OTIC EVENT | Otonomy, Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022240277-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | UNIVERSITE EURO-MEDITERRANEENNE DE FES (MA) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122991-A1 | GROWTH FACTOR FORMULATION FOR CONDITION ASSOCIATED WITH OTIC EVENT | AREG, FGF1, HDGF | GSTP1 4806/4885GSTA1 4665/4885CYP2C9 4863/4885 |
| US-20230190642-A1 | GROWTH FACTOR OTIC FORMULATIONS | AREG, HDGF, NGF | GSTP1 4842/4885GSTA1 4754/4885CYP2C9 4862/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | GSTP1 3386/4885GSTA1 2859/4885CYP2C9 3788/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GSTP1 4525/4885GSTA1 3920/4885CYP2C9 4732/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | GSTP1 4525/4885GSTA1 3920/4885CYP2C9 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.